<DOC>
	<DOCNO>NCT02625155</DOCNO>
	<brief_summary>The purpose study determine whether addition selective pharmacogenomic ( PGx ) test determine Urine Drug Testing ( UDT ) add clinical benefit evidence reduction Target Drug-related Adverse Events ( TDRAE ) period follow enrollment .</brief_summary>
	<brief_title>Standard Care Versus Urine Testing With Selective PHarmacogenomics Effective Drug Dosing REgimens</brief_title>
	<detailed_description />
	<criteria>1 . Subject 12 year age old ; 2 . Subject legal representative able willing provide inform consent ; 3 . Subject TDRAE include ineffective therapeutic response within last 60 day new patient treating healthcare provider 's practice ; 4 . Subject schedule plan schedule UDT , order per treat healthcare provider 's local standard care ; 5 . Subject currently receive subject 's treating healthcare provider consider treatment least one target drug list metabolize one gene consider study : Amitriptyline , Imipramine , Diazepam , Alprazolam , Codeine , Hydrocodone , Oxycodone , Methadone , Meperidine , Fentanyl Carisoprodol . 1 . Prior history PGx test gene specific target drug past ; 2 . PGx test deemed mandatory opinion treat healthcare provider ; 3 . History liver renal transplantation ; 4 . Receiving chronic hemodialysis peritoneal dialysis ; 5 . Currently hospitalize longterm care facility ; 6 . Participation another clinical trial would , Investigator 's opinion , interfere conduct study ; 7 . Subject subject 's guardian advocate unable provide accurate history subject 's medical history , medication , symptom .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pharmacogenomics</keyword>
	<keyword>Urine Drug Testing</keyword>
	<keyword>antidepressant</keyword>
	<keyword>benzodiazepine</keyword>
	<keyword>opioids</keyword>
	<keyword>muscle relaxant</keyword>
	<keyword>non-steroidal anti-inflammatory agent</keyword>
	<keyword>TDRAE</keyword>
</DOC>